ARCHIVES

Motesanib Does Not Improve OS; Study Doesn’t Meet Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 4 | April 29, 2011

Download PDF Visit The Full Archive

Related Articles

Includes May Business & Regulatory Report (8-page issue).

June 6, 2003

In Brief: Lippman Leads M.D. Anderson Clinical Prevention; Baylin Named Ludwig Professor

May 10, 1996

Drug Development: Tivozanib Trial Discontinued Due to Insufficient Enrollment

February 7, 2014

Tivozanib Trumps Sorafenib In 1st-Line Renal Cancer Study

May 25, 2012

Chabner Cautions Against Downsizing, Consolidation Of NCI Intramural Programs

March 3, 1995

DCPC advisors OK 16 Year Trial Of Screening Methods

February 15, 1991